Abstract:Therapeutic Advances in Drug Safety, Volume 15, Issue , January-December 2024. Background:Adverse drug reactions (ADRs) contribute significant clinical and economic burden to the country's healthcare system globally. Prompt reporting of ADRs by the community pharmacist is essential to the active pharmacovigilance program.Objectives:This study assesses private community pharmacists' knowledge, attitude, and practice (KAP) about ADRs and reporting.Design:A cross-sectional, qualitative study was performed using a pre-validated self-administered questionnaire.Methods:This self-administered questionnaire was conducted at community pharmacies between March and July 2022. The data collected were analyzed using the Mann–Whitney and Kruskal–Wallis tests to examine the differences in overall KAP scores with a subgroup of sociodemographic characteristics of the study participants. Logistic regression analysis was used to analyze the predictors of practice.Results:In total, 156 fully completed questionnaires were collected by the community pharmacists. A positive association between the designation, qualification, and work experience with the total scores of the respondents was observed (p < 0.05). Among the predictors of ADR reporting practice, a significant association was observed with knowledge score (⩾6, p = 0.0219), designation (pharmacists, p = 0.0102), qualification (masters, p = 0.0002), and work experience (⩾11 years, p = 0.0184). Most community pharmacists had good knowledge and attitude but poor practice toward reporting ADRs. Uncertainty of how and where to report, lack of training, lack of reporting forms, and insufficient clinical knowledge were the practice-based barriers in the ADR reporting process.Conclusion:Though the study found sufficient understanding and favorable views on ADR reporting, participants reported poor practices and barriers to reporting ADR. Therefore, structured continuing professional development programs for community pharmacists are needed to overcome the barriers and enhance the practice of ADR reporting.Plain language summaryKnowledge, attitude, and practice of community pharmacists toward medicine side effectsIntroduction:Medicines aren't safe because they can have bad side effects that can cause major health problems for the patient. These fears make it more important and show how valuable it is to report side effects. This study examines community pharmacists' knowledge, attitude, and practices (KAP) in the United Arab Emirates about side effects and how often people tell them.Methods:A structured questionnaire was used to collect information on the profiles of community pharmacists and their knowledge, views, and practices regarding adverse effects. The purpose was to discover what stops pharmacists from reporting adverse effects and suggest ways to improve reporting. We used statistical tests to examine the total KAP results and information about the study subjects' backgrounds.Results:Out of 177 community pharmacists who filled out the form, only 156 completed it. The study found that people had good understanding and attitude scores but poor behaviors when reporting side effects. The main things that kept pharmacists from reporting side effects were not knowing how and where to report them, not having a reporting form, and not having enough training and knowledge about reporting.Conclusion:The study found that private community pharmacists know a lot about drugs and have positive views. However, they don't always follow through with good advice, and there aren't many good reasons why people don't report unpleasant effects. Education and training programs about side effects might help people overcome the problems and get more neighborhood pharmacists to write about them. This will improve the standard of patient care and the safe and effective use of drugs.

UK Patients’ Reports of Adverse Reactions Are More Detailed Than Doctors’

How Patient Reporters Identify Adverse Drug Reactions

Factors affecting patient reporting of adverse drug reactions: a systematic review

The Importance of Direct Patient Reporting of Adverse Drug Reactions in the Safety Monitoring Process

Patient report on information given, consultation time and safety in primary care

Identification of suspected fatal adverse drug reactions by paediatricians: a UK surveillance study

Adverse Drug Reaction Reporting Quality among Different Health Professionals and the Contribution of Clinical Pharmacists: A Pilot Study

Sustained Decline of Direct General Practitioner Reporting of Adverse Drug Reactions in Australia and Paucity in Details of Australian Reports in Safety Advisories

Patient versus clinician symptom reporting using the National Cancer Institute Common Terminology Criteria for Adverse Events: results of a questionnaire-based study

Implementation and results of active vaccine safety monitoring during the COVID-19 pandemic in the UK

Evaluation of a simplified pharmacovigilance tool for general practitioners: 5 years of insight

Effect of An Educational Intervention to Improve Adverse Drug Reaction Reporting in Physicians: A Cluster Randomized Controlled Trial

Consumers' knowledge and experiences of adverse drug reaction reporting in Australia: a national survey

Quality Analysis of the Adverse Drug Reactions Reports from Shanghai Healthcare Professionals

Patient expectations and awareness of information regarding adverse reactions in drug labelling in China

Exploring the community pharmacist's knowledge, attitude, and practices regarding adverse drug reactions and its reporting in the United Arab Emirates: a survey-based cross-sectional study

Prevalence, characteristics, and reporting of adverse drug reactions in an Australian hospital: a retrospective review of hospital admissions due to adverse drug reactions

A cross-sectional study: comparison of public perceptions of adverse drug reaction reporting and monitoring in eastern and western China

Potential negative impact of informing patients about medication side effects: a systematic review

Patients' Identification, Management and Prevention of Adverse Drug Reactions: A Cross-Sectional Survey of Patients with Severe Adverse Drug Reactions

Reporting of clinical trial safety results in ClinicalTrials.gov for FDA-approved drugs: A cross-sectional analysis